profit from every $100 of sales.
$0$100
Pacific Biosciences of California
$1.96-0.51% today
+20.2% in 1 year
1-year low $1.111-year high $2.90
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Pacific Biosciences of California sold, what it kept, and what it did with the cash.
Sales went from $128 million in 2022 to $160 million in 2025, with -$546 million of profit last year.
SalesProfit
Pacific Biosciences of California vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Pacific Biosciences of California | No profit yet | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads Pacific Biosciences of California's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 128 | 201 | 154 | 160 | |
| 49 | 53 | 37 | 46 | |
| -305 | -310 | -291 | -558 | |
| -282 | -277 | -243 | -153 | |
| -314 | -307 | -310 | -546 | |
| -1.40 | -1.21 | -1.58 | -1.82 | |
| 38.2% | 26.3% | 24.2% | 28.6% | |
| -237.6% | -154.8% | -188.7% | -348.5% | |
| -244.9% | -153.0% | -201.2% | -341.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,767 | 1,746 | 1,260 | 784 |
| Cash | 325 | 180 | 55 | 64 |
| Total debt | 948 | 934 | 672 | 702 |
| Total liabilities | 1,204 | 1,045 | 754 | 779 |
| 563 | 701 | 507 | 5 | |
| 225 | 254 | 288 | 300 | |
| -15.7% | -14.7% | -19.8% | -60.2% | |
| -55.8% | -43.7% | -61.2% | -10,214.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -263 | -259 | -206 | -111 | |
| 17 | 9 | 6 | 8 | |
| -280 | -268 | -212 | -119 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 79 | 72 | 71 | 42 |
Valuation
- –
- –
- –
- 144.8×
- 3.8×
- –
- –
- -19.4%
- -89.3%
- 0.0%
Profitability
- 28.6%
- -348.5%
- -341.5%
- -91.4%
- -22.7%
- -29.5%
- -488.4%
- -16.4%
- -22.7%
- 54.9%
Growth
- +7.6%
- –
- +46.3%
- –
- +10.2%
Financial health
- –
- 297.29
- 89.9%
- -46.8×
- 5.65
- 4.87
- 0.20
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 17%of 952
Bottom 41%of 886
Bottom 4%of 987
What analysts expect
- Average price target
- $1.00
- Range
- $1.00 – $1.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.12 | -0.17 | +29.4% |
| Feb 12, 2026 | -0.12 | -0.19 | +36.8% |
| Nov 5, 2025 | -0.12 | -0.16 | +25.0% |
| Aug 7, 2025 | -0.13 | -0.18 | +27.8% |
| May 8, 2025 | -0.15 | -0.19 | +21.1% |
| Feb 13, 2025 | -0.20 | -0.20 | +0.0% |
| Nov 7, 2024 | -0.22 | -0.22 | +0.0% |
| Aug 7, 2024 | -0.20 | -0.24 | +16.7% |
News
DOJ expected to opine on Union Pacific/Norfolk Southern deal in coming weeks - reportSeeking Alpha · Nov 9, 2026Central Pacific Financial Corp. Q3 2026 Earnings Call SummaryYahoo Finance · Oct 28, 2026CoreWeave expands AI computing capacity in Denmark; adds network locations across Asia Pacific, Middle EastSeeking Alpha · Oct 27, 2026Elbit Systems wins $200M in Asia-Pacific airborne defense contractsSeeking Alpha · Oct 26, 2026Union Pacific Corporation Q3 2026 Earnings Call SummaryYahoo Finance · Oct 22, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
15No pass
Benjamin Graham
43No pass
Philip Fisher
17No pass
Peter Lynch
18No pass
Joel Greenblatt
0No pass
Charlie Munger
19No pass
Terry Smith
21No pass
Questions about Pacific Biosciences of California
Is Pacific Biosciences of California a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Pacific Biosciences of California AI analysis
What does Pacific Biosciences of California do?
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. It is in Medical - Devices.
Does Pacific Biosciences of California pay a dividend?
No. Pacific Biosciences of California does not pay a dividend at the moment.
Is Pacific Biosciences of California stock halal?
No. Pacific Biosciences of California does not pass our halal screen: its debt is 115% of its market value, at or above the 33% limit. How we check
How has Pacific Biosciences of California stock done over the past year?
Up 20.2% over the past twelve months, to $1.96. It traded between $1.11 and $2.90 and is 32.4% below its high.
Who are Pacific Biosciences of California's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Pacific Biosciences of California's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.